Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Halogenated hydrocarbon doai
Patent
1994-05-06
1996-01-02
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Halogenated hydrocarbon doai
514744, 514745, 514746, 514747, 514748, 514749, 514750, 514751, 514757, 514759, 514912, A01N 2900, A61K 3102
Patent
active
054809142
ABSTRACT:
Nonaqueous thixotropic drug delivery vehicles for use in aqueous physiological systems are disclosed comprising a substantially homogeneous dispersion of at least one suspending aid in a nonaqueous perfluorocarbon or fluorinated silicone liquid carrier. Pharmaceutical compounds may be incorporated to provide thixotropic pharmaceutical compositions having improved delivery profiles and high drug localization. The thixotropic compositions act as free-flowing, drop-instillable liquids upon the application of stress yet behave as a visco-elastic material when at rest. Due to these thixotropic properties the pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not degrade the incorporated therapeutic or diagnostic compounds making them well suited for multidose packaging and administration.
REFERENCES:
patent: 3911138 (1975-10-01), Clark, Jr.
patent: 3962439 (1976-06-01), Yokoyama et al.
patent: 3968245 (1976-07-01), Higuchi
patent: 3989843 (1976-11-01), Chabert et al.
patent: 4035506 (1977-07-01), Lucas et al.
patent: 4105798 (1978-08-01), Moore et al.
patent: 4115544 (1978-09-01), Sheil
patent: 4168308 (1979-09-01), Wretlind et al.
patent: 4366169 (1982-12-01), White
patent: 4426374 (1984-01-01), Wheeler
patent: 4452818 (1984-06-01), Haidt
patent: 4490351 (1984-12-01), Clark, Jr.
patent: 4649047 (1987-03-01), Kaswan
patent: 4865846 (1989-09-01), Kaufman
patent: 4882150 (1989-11-01), Kaufman
patent: 4889525 (1989-12-01), Yuhas et al.
patent: 4917930 (1990-04-01), McCormick
patent: 4942179 (1990-07-01), Borgarello et al.
patent: 4990283 (1991-02-01), Visca et al.
G. Meseguer et al., "Gamma scintigraphic study of precorneal drainage . . . in rabbits . . . ," 1993, 95:229-234, International Journal of Pharmaceuticals.
G. R. Snibson et al., "Precorneal Residence Times of Sodium Hyaluronate Solutions Studied by Quantitative Gamma Scintigraphy," 1990, 4:594-602, Eye.
"CAB-O-SIL.RTM. TS-610 Treated Fumed Silica", Technical Data Sheet, Cabot Corporation, Tuscola, Ill., undated, 1 page.
"CAB-O-SIL.RTM. Fumed Silica Properties and Functions," undated, 33 pages.
"CAB-O-SIL.RTM. TS-530 Treated Fumed Silica", Technical Data sheet, Cabot Corporation, Tuscola, Ill., undated, 1 page.
"CAB-O-SIL.RTM. TS-720 Treated Fumed Silica", Technical Data Sheet, Cabot Corporation, Tuscola, Ill., undated, 1 page.
Allergan Inc.
Nutter Nathan M.
LandOfFree
Nonaqueous thixotropic drug delivery suspensions and methods of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonaqueous thixotropic drug delivery suspensions and methods of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonaqueous thixotropic drug delivery suspensions and methods of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-235578